Cite
MLA Citation
Yunpeng Yang et al.. “Efficacy, safety, and biomarker analysis of ensartinib in crizotinib-resistant, ALK-positive non-small-cell lung cancer: a multicentre, phase 2 trial.” Lancet, vol. 8, no. 1, 2020, pp. 45–53. http://access.bl.uk/ark:/81055/vdc_100098438751.0x000008